New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
10:04 EDTCLSN, HTGCCelsion closes second $5M tranche under Hercules Loan Facility Agreement
Celsion (CLSN) announced that it has closed the second $5M tranche under its $20M Loan and Security Agreement dated as of November 25, 2013 with Hercules Technology (HTGC). The proceeds will be used to fund the $3.4M upfront cash payment associated with Celsion's acquisition of EGEN, which was announced separately today, as well as Celsion's transaction costs associated with the EGEN transaction. Upon the closing of this second tranche, Celsion has drawn down a total of $10M under the November 25, 2013 agreement with Hercules. The funding is in the form of secured indebtedness bearing interest at a floating prime-based variable rate. In conjunction with the November 2013 loan agreement, Celsion issued Hercules a warrant exercisable for a total of 194,986 shares of Celsion's common stock at a per share exercise price of $3.59, with 50% immediately exercisable and the remaining 50% exercisable upon Hercules' funding of this $5M draw-down. The Hercules Warrant will expire November 25, 2018.
News For CLSN;HTGC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
10:02 EDTCLSNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:57 EDTCLSNCelsion initiated with a Buy at Cantor
Subscribe for More Information
October 29, 2014
08:18 EDTCLSNCelsion presents positive data for its Therasilence platform
Celsion presented data related to TheraSilence, its lung-specific RNA delivery technology, at the miRNA World Conference Workshop on miRNA Delivery in Boston, MA. The data highlighted formulation characteristics of the TheraSilence delivery platform, preclinical proof-of concept data and data supportive of GEN-2, Celsion's RNA interference therapeutic for the treatment of lung cancer. Celsion acquired the TheraSilence platform and GEN-2 through its acquisition of EGEN, Inc. in June. Intravenous delivery of RNA inhibiting VEGFR-2, a tumor angiogenesis factor, with the TheraSilence delivery system resulted in significant knockdown of VEGFR-2 transcript in lungs, reduction in tumor blood vessel density and inhibition of tumor growth. Systemically administered RNA complexes using the TheraSilence delivery system demonstrated a good tolerability profile.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use